The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

Researchers developed a novel calculator may help to tailor pain medication regimens to patients with SCD seeking emergency ...

The following is a summary of “Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 ...

Hydroxyurea showed more dose-limiting toxicities than placebo but reduced clinical AEs and improved hematological parameters, ...

Pociredir is under clinical development by Fulcrum Therapeutics and currently in Phase I for Sickle Cell Disease.

Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty ...

At that stage, a patient’s cells are edited with Crispr. Sickle cell disease arises from errors in a gene that makes hemoglobin, the substance that carries oxygen throughout the body and gives ...

The targeted protein degrader BMS-986470 from Bristol Myers Squibb (BMS) boosts levels of fetal hemoglobin in cells, mice, and monkeys, the company reported this weekend at the American Society of ...

When symptoms occur, this treatment may help to increase hemoglobin levels, improve fatigue, and decrease bone pain and myalgia (muscle pain). While beta thalassemia disorders are traditionally ...